Cargando…

Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions

The discovery of induced pluripotent stem cells (iPSCs) revolutionized the approach to cell therapy in regenerative medicine. Reprogramming of somatic cells into an embryonic‐like pluripotent state provides an invaluable resource of patient‐specific cells of any lineage. Implementation of procedures...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera, Teresa, Zhao, Yuanyuan, Ni, Yuhui, Wang, Jiwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507179/
https://www.ncbi.nlm.nih.gov/pubmed/32649060
http://dx.doi.org/10.1002/cpsc.117
_version_ 1783585178573078528
author Rivera, Teresa
Zhao, Yuanyuan
Ni, Yuhui
Wang, Jiwu
author_facet Rivera, Teresa
Zhao, Yuanyuan
Ni, Yuhui
Wang, Jiwu
author_sort Rivera, Teresa
collection PubMed
description The discovery of induced pluripotent stem cells (iPSCs) revolutionized the approach to cell therapy in regenerative medicine. Reprogramming of somatic cells into an embryonic‐like pluripotent state provides an invaluable resource of patient‐specific cells of any lineage. Implementation of procedures and protocols adapted to current good manufacturing practice (cGMP) requirements is critical to ensure robust and consistent high‐quality iPSC manufacturing. The technology developed at Allele Biotechnology for iPSC generation under cGMP conditions is a powerful platform for derivation of pluripotent stem cells through a footprint‐free, feeder‐free, and xeno‐free reprogramming method. The cGMP process established by Allele Biotechnology entails fully cGMP compliant iPSC lines where the entire manufacturing process, from tissue collection, cell reprogramming, cell expansion, cell banking and quality control testing are adopted. Previously, we described in this series of publications how to create iPSCs using mRNA only, and how to do so under cGMP conditions. In this article, we describe in detail how to culture, examine and storage cGMP‐iPSCs using reagents, materials and equipment compliant with cGMP standards. © 2020 The Authors. Basic Protocol 1: iPSC Dissociation Support Protocol 1: Stem cell media Support Protocol 2: ROCK inhibitor preparation Support Protocol 3: Vitronectin coating Basic Protocol 2: iPSC Cryopreservation Basic Protocol 3: iPSC Thawing
format Online
Article
Text
id pubmed-7507179
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75071792020-09-28 Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions Rivera, Teresa Zhao, Yuanyuan Ni, Yuhui Wang, Jiwu Curr Protoc Stem Cell Biol Protocol The discovery of induced pluripotent stem cells (iPSCs) revolutionized the approach to cell therapy in regenerative medicine. Reprogramming of somatic cells into an embryonic‐like pluripotent state provides an invaluable resource of patient‐specific cells of any lineage. Implementation of procedures and protocols adapted to current good manufacturing practice (cGMP) requirements is critical to ensure robust and consistent high‐quality iPSC manufacturing. The technology developed at Allele Biotechnology for iPSC generation under cGMP conditions is a powerful platform for derivation of pluripotent stem cells through a footprint‐free, feeder‐free, and xeno‐free reprogramming method. The cGMP process established by Allele Biotechnology entails fully cGMP compliant iPSC lines where the entire manufacturing process, from tissue collection, cell reprogramming, cell expansion, cell banking and quality control testing are adopted. Previously, we described in this series of publications how to create iPSCs using mRNA only, and how to do so under cGMP conditions. In this article, we describe in detail how to culture, examine and storage cGMP‐iPSCs using reagents, materials and equipment compliant with cGMP standards. © 2020 The Authors. Basic Protocol 1: iPSC Dissociation Support Protocol 1: Stem cell media Support Protocol 2: ROCK inhibitor preparation Support Protocol 3: Vitronectin coating Basic Protocol 2: iPSC Cryopreservation Basic Protocol 3: iPSC Thawing John Wiley and Sons Inc. 2020-07-10 2020-09 /pmc/articles/PMC7507179/ /pubmed/32649060 http://dx.doi.org/10.1002/cpsc.117 Text en © 2020 The Authors. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Protocol
Rivera, Teresa
Zhao, Yuanyuan
Ni, Yuhui
Wang, Jiwu
Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
title Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
title_full Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
title_fullStr Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
title_full_unstemmed Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
title_short Human‐Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions
title_sort human‐induced pluripotent stem cell culture methods under cgmp conditions
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507179/
https://www.ncbi.nlm.nih.gov/pubmed/32649060
http://dx.doi.org/10.1002/cpsc.117
work_keys_str_mv AT riverateresa humaninducedpluripotentstemcellculturemethodsundercgmpconditions
AT zhaoyuanyuan humaninducedpluripotentstemcellculturemethodsundercgmpconditions
AT niyuhui humaninducedpluripotentstemcellculturemethodsundercgmpconditions
AT wangjiwu humaninducedpluripotentstemcellculturemethodsundercgmpconditions